Compared to sulfonylureas and metformin, liraglutide demonstrates advantages in glycemic control (assessed by HbA1c levels) and reduction of liver fat content (LFC) in patients with MASLD and T2DM, with a more significant difference observed over sulfonylureas
Ideal for Active LifestylesPerfect for athletes and those engaged in regular exercise, helping to reduce fatigue and improve recovery
Accepted: Apr 16, 2025 DOI: Download citation
And sometimes people do experience relief when their body changes
adults and 1 billion people worldwide are clinically obese 2,3 Demand is Growing Used to treat diabetes for more than 10 years 4 Diabetes Treatment Diverse Application Potential Weight Loss Reduced Cardiovascular and Stroke Risk Impulsive Behavior Reduction Sleep Apnea Treatment Diabetes Management and Prevention Preventative Health Care Explore our Weight Loss ETF: Amplify Weight Loss Drug & Treatment ETF Access a global equity portfolio of companies pioneering GLP-1 therapies and the broader supply chain to capitalize on demand

GLP-1 for sleep apnea, alcohol use and cancer risk GLP-1s may address conditions well beyond metabolic diseases: Obstructive sleep apnea: Emerging data suggest GLP-1s improve apnea symptoms. Alcohol use disorder: Patients using liraglutide or semaglutide reduced alcohol consumption by nearly two-thirds. Obesity-related cancers: An observational study of 6,000 adults found that GLP-1 receptor agonists halved the risk of obesity-related cancers compared with usual care